search
  • Home
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • News
    • Events
    • Careers
  • Research & Pipeline
    • Paxalisib
    • Cantrixil
    • Collaborations
    • Publications & Presentations
  • Partnering
  • Investor Centre
    • ASX Announcements
    • SEC Filings
    • Company Reports
    • Company Meetings
    • Corporate Presentations
    • Analyst Reports
    • Investor Newsletters
    • Shareholder Services
    • COVID-19
    • Entitlement Offer
  • Media Centre
    • Video
    • Insights
MENU
  • Home
  • About Us
    • Overview
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • News
    • Events
    • Careers
  • Research & Pipeline
    • Overview
    • Paxalisib
    • Cantrixil
    • Test
    • Collaborations
    • Publications & Presentations
  • Partnering
  • Investor Centre
    • Overview
    • ASX Announcements
    • SEC Filings
    • Company Reports
    • Company Meetings
    • Corporate Presentations
    • Analyst Reports
    • Investor Newsletters
    • Shareholder Services
    • COVID-19
    • Entitlement Offer
  • Media Centre
    • Video
    • Insights
  • CONTACT US
  • /
  • Media Centre
  • /
  • Insights
  • Media Centre
  • Overview
  • Video
  • Insights
  • 14-Feb-2019Media release

    February 2019 Shareholder Newsletter

    Kazia Therapeutics is pleased to make its February 2019 newsletter available to investors.

    Read More

  • 13-Feb-2019Media release

    Dr Alan Olivero discusses what makes a good brain cancer drug

    Dr Alan Olivero, who led the team at Genentech that developed GDC-0084, discusses what makes a good brain cancer drug.

    Read More

  • 11-Jan-2019General

    Proactive Investors speaks with Kazia CEO Dr James Garner

    Our CEO, Dr James Garner sat down with Christine Corrado from Proactive Investors at the 11th Annual Biotech Showcase in San Francisco last week to discuss the multiple data readouts rapidly approaching for our GDC-0084 and Cantrixil clinical trial programs.

    Read More

  • 12-Nov-2018Media release

    2018 Annual General Meeting Presentation Webcast

    Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to invite investors to view an archived copy of CEO, Dr James Garner’s address from the company’s 2018 AGM, together with questions and answers relating to the presentation.

    Read More

  • 05-Nov-2018Media release

    November 2018 Shareholder Newsletter

    Kazia Therapeutics is pleased to make its November 2018 newsletter available.

    Read More

  • 31-Oct-2018General

    Morgans interview with Kazia CEO Dr James Garner

    Kazia Therapeutics CEO Dr James Garner was interviewed recently by Morgans Senior Analyst Scott Power about Kazia’s upcoming milestones and clinical trials.

    Read More

  • 24-Oct-2018General

    Potential glioblastoma therapy GDC-0084 presented to Finance News Network audience

    Kazia Therapeutics CEO Dr James Garner was a key speaker at a Finance News Network event in Sydney last week.

    Read More

  • 22-Oct-2018Media release

    Kazia enters clinical collaboration to study use of brain cancer drug GDC-0084 in breast cancer

    The Australian oncology-focused biotech Kazia Therapeutics announced today that it will collaborate with world-leading treatment and research centre Dana-Farber Cancer Institute to investigate the use of Kazia’s potential new therapy for brain cancer, GDC-0084, in breast cancer that has spread to the brain.

    Read More

  • 13-Sep-2018Media release

    Australian clinical trial of ovarian cancer therapy Cantrixil pivotal for cancer stem cell research

    The Australian phase 1 clinical trial of the drug Cantrixil for recurrent ovarian cancer could shape the next wave of clinical research into drugs targeting cancer stem cells, a peer-reviewed paper published in Expert Opinion on Orphan Drugs this month has found.

    Read More

  • 25-Jul-2018General

    Sydney Shareholder Information Session July 2018

    Kazia Therapeutics hosted briefing sessions for shareholders in Sydney and Melbourne this month.

    Read More

    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
  • Subscribe to Insights

    Enter your email address to subscribe to our insights and receive notifications of new posts by email.

    Required values are marked



    Submit
  • SITE MAP
  • /
  • PRINT PAGE
  • /
  • TERMS OF USE
  • /
  • PRIVACY

  • FORWARD-LOOKING STATEMENTS
  • /
  • COOKIE POLICY
SITE BY SPATIAL DESIGN